Hemab Therapeutics Secures $157 Million in Series C Funding
Hemab Therapeutics has raised $157 million in an oversubscribed Series C funding round to advance its pipeline of treatments for rare and underserved bleeding disorders, according to an October 27 announcement. The financing was led by Sofinnova Partners, with major participation from an unnamed global asset management company.
Existing backers Novo Holdings, RA Capital Management, and Rock Springs Capital also contributed, alongside new investors including Qatar Investment Authority and Avoro Capital Advisors. Hemab plans to use the proceeds to support the development of sutacimig, a midstage candidate being positioned as the first prophylactic treatment for Glanzmann thrombasthenia. The company said it aims to close gaps in current treatment options and deliver more comprehensive solutions for patients with limited therapies.
Advancing Novel Therapies
“The quality of our investor syndicate and this significant financing validate our approach and enable us to continue building what we believe will become the ultimate clotting company,” said CEO Benny Sorensen, M.D., Ph.D. He added that Hemab’s expertise in clotting science and its track record in drug development position the company to deliver novel therapies for patients.
Lead Candidate: Sutacimig
Sutacimig, Hemab’s lead program, is a bispecific antibody designed to mimic the function of factor VIIa, a key clotting protein, by targeting activated platelets at bleeding sites. In a phase 2 study, the therapy produced a clinically meaningful reduction in bleeding episodes, the company reported. Hemab plans to evaluate sutacimig next in patients with factor VII deficiency.
Glanzmann thrombasthenia is a rare inherited condition caused by a deficiency in platelet integrin alpha IIb beta3, which prevents blood from clotting effectively. Hemab aims to make sutacimig the first preventative therapy available for this disorder.
Expanding the Pipeline
The company’s second clinical candidate, HMB-002, is a monovalent antibody in development for von Willebrand disease. Data to date indicate the therapy can increase von Willebrand factor and factor VIII levels, directly targeting the disease’s underlying mechanism. Hemab expects to move HMB-002 into a registration study with support from the new funding.
As the programs advance, the company said it intends to integrate insights from its natural history studies to better align its research with patients’ real-world experiences.
Future Outlook and Strategy
The biotech’s latest financing follows a $135 million Series B round in 2023 and a $55 million Series A in 2021. Sofinnova Partners’ Joe Anderson, Ph.D., who joined Hemab’s board as part of the new funding, said the company’s scientific depth and clinical execution make it a standout in the biotech field.
Hemab’s long-term pipeline strategy, described as the “1-2-5” plan, originally focused on bringing five assets to the clinic by 2025 and now centers on progressing five development projects by that time. Alongside sutacimig and HMB-002, Hemab plans to introduce another candidate, HMB-003, in 2026.
According to Sorensen, the company is pursuing opportunities in bleeding disorders where progress has been limited compared with more common conditions like hemophilia. He noted that developing treatments for these smaller patient groups requires greater scientific innovation and complex bioengineering.
Sorensen said Hemab’s recent fundraise was met with strong investor interest, describing the round as “significantly oversubscribed.”
